Cognition announces Phase 2 ‘SHIMMER’ study to be presented at ILBDC

Cognition Therapeutics (CGTX) announced that JamesGalvin, MD, MPH will present topline results from the ‘SHIMMER’ study of zervimesine in dementia with Lewy bodies during an oral presentation at the International Lewy Body Dementia Conference, ILBDC. Dr. Galvin is director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine and was the study director and principal investigator on the SHIMMER study grant from the National Institute of Aging. The Phase 2 SHIMMER study randomized 130 adults with mild-to-moderate DLB who took a daily oral dose of zervimesine or placebo for six months. The study met its primary endpoint of safety and tolerability. As will be presented at ILBDC, zervimesine-treated DLB patients scored an average of 86% better than placebo-treated patients on the neuropsychiatric inventory A-L at the end of the study.